Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gabriel Dickstein is active.

Publication


Featured researches published by Gabriel Dickstein.


Endocrinologist | 1997

Low-Dose ACTH Stimulation Test

Gabriel Dickstein; Eldad Arad; Carmela Shechner

Most symptoms and signs of adrenal insufficiency are nonspecific yet common. Because the disorder is life threatening but very easy to treat, it is essential that it be accurately diagnosed. A test that is simple, inexpensive, and accurate is needed for this purpose. The tests available in the past


Current Opinion in Endocrinology, Diabetes and Obesity | 2008

Low-dose and high-dose adrenocorticotropin testing: indications and shortcomings.

Gabriel Dickstein; Leonard Saiegh

Purpose of reviewThe 250 μg adrenocorticotropin test (high-dose test) is the most commonly used adrenal stimulation test, though the use of physiologic doses (1.0 μg or 0.5 μg/1.73 m2) (low-dose test) has recently gained wider acceptance. These variants and the use of adrenocorticotropin test in the ICU, however, remain controversial. The validity of the low-dose test and the parameters for evaluation of high- and low-dose tests in different situations need reevaluation. Recent findingsIn the last few years, numerous studies have used the low-dose test as a single test following previous findings that it is more sensitive and accurate than the high-dose test. It is used mainly in secondary adrenal insufficiency and after treatment with therapeutic glucocorticosteroids to define hypothalamo-pituitary-adrenal suppression. Unless there is a very recent onset of disease, the results are interpreted by most researchers as diagnostic. The treatment of relative adrenal insufficiency, based on delta cortisol, has not yielded proof of correlation between this diagnosis and better prognosis with glucocorticoid treatment. SummaryFor interpretation of an adrenocorticotropin test, only peak – and not delta – cortisol should be used. The use of 240–300 mg of hydrocortisone daily in ICU patients, including septic shock, should be considered as pharmacologic, rather than as a replacement dose. Using the low-dose test for this purpose will lead to further misdiagnosis.


European Journal of Obstetrics & Gynecology and Reproductive Biology | 2012

Adrenalectomy for adrenocortical adenoma causing Cushing's syndrome in pregnancy: a case report and review of literature

Rami N. Sammour; Leonard Saiegh; Ibrahim Matter; Ron Gonen; Carmela Shechner; Max Cohen; Gonen Ohel; Gabriel Dickstein

We present a case of adrenocorticotropic hormone (ACTH)-independent Cushings syndrome diagnosed in a patient in the third trimester of her pregnancy, with an adrenal mass observed on imaging studies. Laparoscopic adrenalectomy was performed successfully at 32 weeks. To the best of our knowledge, this is the latest gestational age at which laparoscopic adrenalectomy has been reported. We present the various considerations for determining the surgical approach and the optimal timing for surgery. Adrenalectomy during pregnancy for the treatment of Cushings syndrome caused by adrenocortical adenoma has been reported in 23 patients in the English-language medical literature to date and seems safe and beneficial. According to the data, surgical treatment has led to a reduction in perinatal mortality and maternal morbidity rates, but has not affected the occurrence of preterm birth and intrauterine growth restriction. The best outcome can be achieved by a multidisciplinary approach, with a team comprising a maternal-fetal medicine specialist, an endocrinologist and a surgeon. The timing of surgery and the surgical approach need to be determined according to the surgeons expertise, the severity of the condition, the patients preferences, and gestational age. Laparoscopy may prove to be the preferred surgical approach. The small number of cases precludes providing evidence-based recommendations.


The American Journal of the Medical Sciences | 1984

Thyrotoxicosis Induced by Amiodarone, a New Efficient Antiarrhythmic Drug With High Iodine Content

Gabriel Dickstein; Shlomo Amikam; E. Riss; David Barzilai

Amiodarone is an antiarrhythmic agent with high iodine content. Ten patients treated with amiodarone developed thyrotoxicosis. I131 uptakes were negligible, and TT3 levels low in relation to TT4 levels, and sometimes even normal.Cessation of amiodarone caused thyroid functions to return to normal in one to five months, unrelated to propylthiouracil treatment. Eight of the patients had normal thyroid glands on radioscan or palpation. All patients tested had normal TRH tests.Thyrotoxicosis is a relatively common complication of amiodarone treatment, probably caused by its high iodine content. It is possible in apparently normal thyroid glands, suggesting failure of the homeostatic mechanisms controlling thyroid synthesis and release in these patients.Amiodarone is very efficient in controlling tachyarrhythmias and angina pectoris, situations in which thyrotoxicosis is dangerous. Thyroid function tests should therefore be drawn periodically, and the complication considered whenever tachyarrhythmias worsen on treatment with amiodarone.


The Journal of Clinical Endocrinology and Metabolism | 1991

Adrenocorticotropin Stimulation Test: Effects of Basal Cortisol Level, Time of Day, and Suggested New Sensitive Low Dose Test*

Gabriel Dickstein; Carmela Shechner; Wendell E. Nicholson; Itzhak Rosner; Zila Shen-Orr; Fayad Adawi; Michal Lahav


European Journal of Endocrinology | 1997

One microgram is the lowest ACTH dose to cause a maximal cortisol response. There is no diurnal variation of cortisol response to submaximal ACTH stimulation

Gabriel Dickstein; Doron Spigel; Eldad Arad; Carmela Shechner


The Journal of Clinical Endocrinology and Metabolism | 1998

Is There a Role for Low Doses of Mitotane (o,p′-DDD) as Adjuvant Therapy in Adrenocortical Carcinoma?

Gabriel Dickstein; Carmela Shechner; Eldad Arad; Lael-Anson Best; Ofer Nativ


The Journal of Clinical Endocrinology and Metabolism | 2005

On the Term “Relative Adrenal Insufficiency”—or What Do We Really Measure with Adrenal Stimulation Tests?

Gabriel Dickstein


JAMA | 1980

Bromocriptine-Induced Pregnancy in an Acromegalic Patient

Rafael Luboshitzky; Gabriel Dickstein; David A. Barzilai


The Journal of Clinical Endocrinology and Metabolism | 2000

False Positive Metaiodobenzylguanidine Scan in a Patient with a Huge Adrenocortical Carcinoma

Tova Rainis; Simona Ben-Haim; Gabriel Dickstein

Collaboration


Dive into the Gabriel Dickstein's collaboration.

Top Co-Authors

Avatar

Carmela Shechner

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Michal Lahav

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

David A. Barzilai

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

David Barzilai

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Leonard Saiegh

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Zila Shen-Orr

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Alfred Schramek

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

E. Riss

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Gonen Ohel

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Ibrahim Matter

Technion – Israel Institute of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge